Peripheral T-Cell Lymphoma
A heterogeneous group of aggressive non-Hodgkin lymphomas derived from mature T cells. Includes PTCL-NOS, angioimmunoblastic T-cell lymphoma, and ALK-negative anaplastic large cell lymphoma. Generally poor prognosis with standard chemotherapy.
Quick Answer
What it is
A heterogeneous group of aggressive non-Hodgkin lymphomas derived from mature T cells. Includes PTCL-NOS, angioimmunoblastic T-cell lymphoma, and ALK-negative anaplastic large cell lymphoma.
Key findings
- Grade A: Overall Response Rate (PTCL) (Romidepsin (Istodax))
- Grade A: Duration of Response (PTCL) (Romidepsin (Istodax))
- Grade B: Response by Prior Therapy (Romidepsin (Istodax))
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Peripheral T-Cell Lymphoma
- Supplements Studied:1
1 supps · 3 outcomes
Detailed Outcomes
A
Overall Response Rate (PTCL)
Pivotal Phase 2 trial (n=130): ORR 25% with 15% CR/CRu. NCI multicenter study (n=47): ORR 38% with 17% CR. Responses seen across all major PTCL subtypes. Led to FDA approval June 2011.
moderate↑Improves
A
Duration of Response (PTCL)
Pivotal trial: Median DOR 28 months in responders. NCI trial: Median DOR 8.9 months (range 2-74 months). Durable responses possible in heavily pretreated patients (median 3 prior therapies).
large↑Improves
B
Response by Prior Therapy
Responses observed regardless of number or type of prior therapies. Patients with up to 11 prior treatments responded. 38% of patients had prior stem cell transplant and still achieved responses.
moderate↑Improves